{"protocolSection": {"identificationModule": {"nctId": "NCT03254108", "orgStudyIdInfo": {"id": "263-102-00001"}, "secondaryIdInfos": [{"id": "JapicCTI-173676", "type": "OTHER", "domain": "Japic"}], "organization": {"fullName": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}, "briefTitle": "Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure", "officialTitle": "A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group Comparison Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure"}, "statusModule": {"statusVerifiedDate": "2021-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-11-06", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-04-14", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-04-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-08-16", "studyFirstSubmitQcDate": "2017-08-16", "studyFirstPostDateStruct": {"date": "2017-08-18", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-07-08", "resultsFirstSubmitQcDate": "2021-07-08", "resultsFirstPostDateStruct": {"date": "2021-07-28", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-07-08", "lastUpdatePostDateStruct": {"date": "2021-07-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Otsuka Pharmaceutical Co., Ltd.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The dose for intravenous administration of OPC-61815 achieving tolvaptan exposure equivalent to that for oral administration of tolvaptan 15-mg tablet will be investigated by administering OPC-61815 injection 2 to 16mg or tolvaptan 15-mg oral tablet to subjects with congestive heart failure."}, "conditionsModule": {"conditions": ["Congestive Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 61, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "OPC-61815 injection 2mg", "type": "EXPERIMENTAL", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.", "interventionNames": ["Drug: OPC-61815 injection 2mg"]}, {"label": "OPC-61815 injection 4mg", "type": "EXPERIMENTAL", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.", "interventionNames": ["Drug: OPC-61815 injection 4mg"]}, {"label": "OPC-61815 injection 8mg", "type": "EXPERIMENTAL", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.", "interventionNames": ["Drug: OPC-61815 injection 8mg"]}, {"label": "OPC-61815 injection 16mg", "type": "EXPERIMENTAL", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.", "interventionNames": ["Drug: OPC-61815 injection 16mg"]}, {"label": "Tolvaptan tablet 15mg", "type": "ACTIVE_COMPARATOR", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.", "interventionNames": ["Drug: Tolvaptan tablet 15mg"]}], "interventions": [{"type": "DRUG", "name": "OPC-61815 injection 2mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.", "armGroupLabels": ["OPC-61815 injection 2mg"]}, {"type": "DRUG", "name": "OPC-61815 injection 4mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.", "armGroupLabels": ["OPC-61815 injection 4mg"]}, {"type": "DRUG", "name": "OPC-61815 injection 8mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.", "armGroupLabels": ["OPC-61815 injection 8mg"]}, {"type": "DRUG", "name": "OPC-61815 injection 16mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.", "armGroupLabels": ["OPC-61815 injection 16mg"]}, {"type": "DRUG", "name": "Tolvaptan tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.", "armGroupLabels": ["Tolvaptan tablet 15mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Maximum Plasma Concentration (Cmax) of OPC-41061 on Day 1", "timeFrame": "Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug"}, {"measure": "Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC24h) on Day 1", "timeFrame": "Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Subjects who are currently on treatment with any of the following diuretics\n\n   * Loop diuretics equivalent to furosemide tablet or fine granules at a dose of 40 mg/day or higher\n   * Concomitant use of a loop diuretic and a thiazide diuretic (including thiazide analogs) at any dose\n   * Concomitant use of a loop diuretic and an aldosterone antagonist or potassium-sparing diuretic agent at any dose\n2. Subjects with congestive heart failure in whom lower limb edema, pulmonary congestion, and/or jugular venous distension due to volume overload is present\n3. Subjects who are currently hospitalized or who are able to be hospitalized during the trial\n\nExclusion Criteria:\n\n1. Subjects with acute heart failure\n2. Subjects with a history of hypersensitivity to any of ingredients of OPC-61815 or tolvaptan\n3. Subjects who are unable to sense thirst or who have difficulty with fluid intake", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "20 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Hiroaki Ono", "affiliation": "Otsuka Pharmaceutical Co., Ltd.", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Kanto", "country": "Japan"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.", "accessCriteria": "Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 74 subjects were screened for this trial, 13 were screen failures, and 61 were randomly assigned to one of the treatment groups. One subject assigned to the OPC-61815 16-mg group was withdrawn due to dehydration before initiation of the trial drug administration; therefore, 60 subjects received at least 1 dosing of the trial drug.", "groups": [{"id": "FG000", "title": "OPC-61815 Injection 2mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg."}, {"id": "FG001", "title": "OPC-61815 Injection 4mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg."}, {"id": "FG002", "title": "OPC-61815 Injection 8mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg."}, {"id": "FG003", "title": "OPC-61815 Injection 16mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "FG004", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "12"}, {"groupId": "FG004", "numSubjects": "12"}]}, {"type": "Received Treatment", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "11"}, {"groupId": "FG004", "numSubjects": "12"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "12"}, {"groupId": "FG003", "numSubjects": "11"}, {"groupId": "FG004", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "1"}]}, {"type": "AST/ALT is increased to 3 times upper limit of normal or higher", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety Analysis Set: all subjects treated with the investigational medicinal product (IMP) at least once", "groups": [{"id": "BG000", "title": "OPC-61815 Injection 2mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg."}, {"id": "BG001", "title": "OPC-61815 Injection 4mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg."}, {"id": "BG002", "title": "OPC-61815 Injection 8mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg."}, {"id": "BG003", "title": "OPC-61815 Injection 16mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "BG004", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}, {"id": "BG005", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "12"}, {"groupId": "BG005", "value": "60"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "73.7", "spread": "9.5"}, {"groupId": "BG001", "value": "74.5", "spread": "11.9"}, {"groupId": "BG002", "value": "72.2", "spread": "9.9"}, {"groupId": "BG003", "value": "77.9", "spread": "3.8"}, {"groupId": "BG004", "value": "74.8", "spread": "8.9"}, {"groupId": "BG005", "value": "74.6", "spread": "9.1"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "3"}, {"groupId": "BG004", "value": "2"}, {"groupId": "BG005", "value": "19"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "8"}, {"groupId": "BG004", "value": "10"}, {"groupId": "BG005", "value": "41"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "12"}, {"groupId": "BG005", "value": "60"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Japan", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "11"}, {"groupId": "BG004", "value": "12"}, {"groupId": "BG005", "value": "60"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Maximum Plasma Concentration (Cmax) of OPC-41061 on Day 1", "populationDescription": "Subjects treated with the IMP at least once and had at least 1 data of primary endpoint after IMP administration", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug", "groups": [{"id": "OG000", "title": "OPC-61815 Injection 2mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg."}, {"id": "OG001", "title": "OPC-61815 Injection 4mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg."}, {"id": "OG002", "title": "OPC-61815 Injection 8mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg."}, {"id": "OG003", "title": "OPC-61815 Injection 16mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "OG004", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "11"}, {"groupId": "OG004", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41.4", "spread": "11.4"}, {"groupId": "OG001", "value": "98.6", "spread": "43.7"}, {"groupId": "OG002", "value": "149", "spread": "61.7"}, {"groupId": "OG003", "value": "282", "spread": "96.0"}, {"groupId": "OG004", "value": "325", "spread": "194"}]}]}]}, {"type": "PRIMARY", "title": "Area Under the Concentration-time Curve From Time Zero to 24 Hours (AUC24h) on Day 1", "populationDescription": "Subjects treated with the IMP at least once and had at least 1 data of primary endpoint after IMP administration", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*h/mL", "timeFrame": "Baseline, 1, 1.5, 2, 4, 6, 12 24 hours after the start of administration of investigational drug", "groups": [{"id": "OG000", "title": "OPC-61815 Injection 2mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg."}, {"id": "OG001", "title": "OPC-61815 Injection 4mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg."}, {"id": "OG002", "title": "OPC-61815 Injection 8mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg."}, {"id": "OG003", "title": "OPC-61815 Injection 16mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg."}, {"id": "OG004", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "12"}, {"groupId": "OG003", "value": "11"}, {"groupId": "OG004", "value": "12"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "356", "spread": "157"}, {"groupId": "OG001", "value": "983", "spread": "563"}, {"groupId": "OG002", "value": "1340", "spread": "522"}, {"groupId": "OG003", "value": "2400", "spread": "1030"}, {"groupId": "OG004", "value": "2850", "spread": "1580"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Treatment-emergent adverse events (TEAEs) were collected from the start of IMP administration up to 15 days", "description": "Subjects who received at least 1 dose of IMP were included in the safety analysis.", "eventGroups": [{"id": "EG000", "title": "OPC-61815 Injection 2mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.", "deathsNumAffected": 0, "deathsNumAtRisk": 13, "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 7, "otherNumAtRisk": 13}, {"id": "EG001", "title": "OPC-61815 Injection 4mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 1, "seriousNumAtRisk": 12, "otherNumAffected": 7, "otherNumAtRisk": 12}, {"id": "EG002", "title": "OPC-61815 Injection 8mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 4, "otherNumAtRisk": 12}, {"id": "EG003", "title": "OPC-61815 Injection 16mg", "description": "Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.", "deathsNumAffected": 0, "deathsNumAtRisk": 11, "seriousNumAffected": 0, "seriousNumAtRisk": 11, "otherNumAffected": 8, "otherNumAtRisk": 11}, {"id": "EG004", "title": "Tolvaptan Tablet 15mg", "description": "Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.", "deathsNumAffected": 0, "deathsNumAtRisk": 12, "seriousNumAffected": 0, "seriousNumAtRisk": 12, "otherNumAffected": 10, "otherNumAtRisk": 12}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Endocarditis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}], "otherEvents": [{"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Dry eye", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Dry mouth", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Catheter site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Infusion site extravasation", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Thirst", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Vessel puncture site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Hepatic congestion", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Liver disorder", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Vascular access site pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Blood urea increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Blood uric acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Electrocardiogram QT prolonged", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Hypernatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 2, "numAtRisk": 12}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Delirium", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Neurogenic bladder", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Decubitus ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Petechiae", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 12}]}, {"term": "Jugular vein distension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Ver. 21.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 12}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 11}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 12}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Director of Clinical Trials", "organization": "Otsuka Pharmaceutical Co., LTD.", "email": "CL_OPCJ_RDA_Team@otsuka.jp", "phone": "+81-3-6361-7366"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-06-19", "uploadDate": "2021-07-08T19:56", "filename": "Prot_000.pdf", "size": 1800675}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-06-21", "uploadDate": "2021-07-08T19:58", "filename": "SAP_001.pdf", "size": 383474}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Congestive Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077602", "term": "Tolvaptan"}], "ancestors": [{"id": "D000065092", "term": "Antidiuretic Hormone Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M1858", "name": "Tolvaptan", "asFound": "Total volume", "relevance": "HIGH"}, {"id": "M17414", "name": "Vasopressins", "relevance": "LOW"}, {"id": "M4437", "name": "Arginine Vasopressin", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Coag", "name": "Coagulants"}]}}, "hasResults": true}